The protein kinase C inhibitor CGP 41251, a staurosporine derivative with antitumor activity, reverses multidrug resistance
The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
Multidrug resistance (MDR) is frequently associated with overexpression of a 170-kDa P-glycoprotein (Pgp). Data suggest altered protein kinase C (PKC) activity in cells expressing the multidrug-resistant phenotype. The staurosporine derivative CGP 41251, an experimental anticancer drug, has been shown to exert selectivity for inhibition of protein kinase C activity and to exhibit antitumor activity in vitro and in vivo. Here we show that CGP 41251 is also able to reverse MDR. After treatment of the multidrug-resistant human lymphoblastoid cell line CCRF-VCR1000 with 500 nM Adriamycin, cell proliferation was reduced to 81% of untreated controls. A combination of 500 nM Adriamycin with a non-toxic concentration of 150 nM CGP 41251 (IC50 for inhibition of cell proliferation 420 nM CGP 41251) inhibits cell proliferation of CCRF-VCR1000 cells to 29% of untreated controls. In sensitive CCRF-CEM cells no enhancement of Adriamycin-induced cytotoxicity was observed upon addition of 150 nM CGP 41251. Strong synergism of the inhibition of cell proliferation was also observed after concomitant treatment of KB-8511 cells with CGP 41251 and Vinblastine or Adriamycin. Drug-sensitive KB-31 cells could not be further sensitized to Adriamycin or Vinblastine with CGP 41251 doses above 100 nM. Pretreatment with 50-1000 nM CGP 41251 for 30 min led to a dose-dependent increase in the intracellular accumulation of rhodamine 123, a substrate of P-glycoprotein. Treatment of multidrug-resistant CCRF-VCR1000 cells with CGP 41251 for 10 min was sufficient to inhibit the efflux of rhodamine 123. Preincubation with CGP 41251 for 12 or 24 hr did not alter multidrug resistance gene (mdrI)-mRNA levels. CGP 41251, a drug with antitumor efficacy in experimental systems, might offer an attractive combination partner for the treatment of tumors expressing the MDR phenotype.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Besides activators, CGP 41251, an inhibitor of PKC, has also shown anti‐tumor activity and was found to reverse multidrug resistance when combined with adriamycin [130].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [130]
In the citing paper
“Besides activators, CGP 41251, an inhibitor of PKC, has also shown anti‐tumor activity and was found to reverse multidrug resistance when combined with adriamycin [130].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [130]
Citations
Cites
1 retracted
Meyer, T., Regenass, U., Fabbro, D., Alteri, E., Röusel, J., Möller, M., Caravatti, G., & Matter, A. (1989) · International Journal of Cancer · doi:10.1002/ijc.2910430519 · Cited by 407
Self-citationRetractedA surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants
Juliano, R. L., & Ling, V. (1976) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(76)90160-7 · Cited by 3,296
Expression of Multidrug Resistance Gene in Human Cancers
Goldstein, L. J., Galski, H., Fojo, A., Willingham, M., Lai, S.-L., Gazdar, A., Pirker, R., Green, A., Crist, W., Brodeur, G. M., et al. (1989) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/81.2.116 · Cited by 1,290
The regulation of transcription by phosphorylation
Hunter, T., & Karin, M. (1992) · Cell · doi:10.1016/0092-8674(92)90162-6 · Cited by 1,281
Noonan, K. E., Beck, C., Holzmayer, T. A., Chin, J. E., Wunder, J. S., Andrulis, I. L., Gazdar, A. F., Willman, C. L., Griffith, B., Von Hoff, D. D., et al. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.18.7160 · Cited by 714
Tsuruo, T., Iida, H., Tsukagoshi, S., & Sakurai, Y. (1982) · PubMed · Cited by 659
Isolation and genetic characterization of human KB cell lines resistant to multiple drugs
Akiyama, S.-I., Fojo, A., Hanover, J. A., Pastan, I., & Gottesman, M. M. (1985) · Somatic Cell and Molecular Genetics · doi:10.1007/bf01534700 · Cited by 529
How cancer cells evade chemotherapy: sixteenth Richard and Hinda Rosenthal Foundation Award Lecture.
Gottesman, M. M. (1993) · PubMed · Cited by 413
Use of fluorescent dyes as molecular probes for the study of multidrug resistance
Neyfakh, A. A. (1988) · Experimental Cell Research · doi:10.1016/0014-4827(88)90152-8 · Cited by 246
Phorbol esters induce multidrug resistance in human breast cancer cells.
Fine, R. L., Patel, J., & Chabner, B. A. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.2.582 · Cited by 238
Research works printed but not linked: 5
- Benson A. B., 1985, Phase I study of vinblastine and verapamil given hy concurrent iv infusion, Cancer Treat. Rep., 69, 795
- Chaudhary P. M., 1992, Activation of MDRI (P‐ glycoprotein) gene expression in human agonists, Oncology Res., 4, 281
- Dong Z., 1991, In vitro model for intrinic drug resistance: effects of protein kinnse C activators on chemosensitivity of cultured human colon cancer cells, Mol. Phannacol., 19, 563
- Fidler I. J., 1993, Role of the organ environment in the pathogenesis of cancer metastasis, Proc. Amer. Assoc. Cancer Res., 34, 570
- Matter A., 1991, A pharmacological approach to growth regulation of breast cancer cells, Pezcoller Foundation Symp., 2, 227
Cited by
Natural product and natural product derived drugs in clinical trials
Butler, M. S., Robertson, A. A. B., & Cooper, M. A. (2014) · Nat. Prod. Rep. · doi:10.1039/c4np00064a · Cited by 602
Targeting the protein kinase C family: are we there yet?
Mackay, H. J., & Twelves, C. J. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2168 · Cited by 373
The potential for isoenzyme‐selective modulation of protein kinase C
Hofmann, J. (1997) · The FASEB Journal · doi:10.1096/fasebj.11.8.9240967 · Cited by 340
Self-citationTumor microenvironment signaling and therapeutics in cancer progression
Goenka, A., Khan, F., Verma, B., Sinha, P., Dmello, C. C., Jogalekar, M. P., Gangadaran, P., & Ahn, B. (2023) · Cancer Communications · doi:10.1002/cac2.12416 · Cited by 323
Phase I and Pharmacokinetic Study of PKC412, an Inhibitor of Protein Kinase C
Propper, D. J., McDonald, A. C., Man, A., Thavasu, P., Balkwill, F., Braybrooke, J. P., Caponigro, F., Graf, P., Dutreix, C., Blackie, R., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.5.1485 · Cited by 233
Metadata
- Authors
- Utz, I., Hofer, S., Regenass, U., Hilbe, W., Thaler, J., Grunicke, H., & Hofmann, J.
- Affiliations
- Universität Innsbruck (AT)
- Corresponding author
- Hofmann, Johann
- ORCID
- Hofer, Susanne
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 1994-04
- Volume
- 57
- Issue
- 1
- Pages
- 104-110
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2057939330
- Cited by
- 72
- References
- 36
- Citations by year
- 2024: 1 · 2023: 2 · 2021: 1 · 2019: 2 · 2018: 2 · 2017: 2 · 2016: 1 · 2014: 2 · 2012: 1
- FWCI
- 3.31
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- International Journal of Cancer (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Keywords
- staurosporine derivatives, PKC inhibitors, multidrug resistance reversal, P-glycoprotein, multidrug resistance gene 1, doxorubicin, vinblastine, drug efflux inhibition, rhodamine 123 accumulation, synergistic drug combination, lymphoblastoid cell lines, MDR1 mRNA
- MeSH terms
- Alkaloids, Antineoplastic Agents, Carrier Proteins, Doxorubicin, Drug Resistance, Humans, KB Cells, Lymphocytes, Membrane Glycoproteins, Protein Kinase C, Rhodamines, Tumor Cells, Cultured, Vincristine, Gene Expression, Staurosporine, Rhodamine 123, ATP Binding Cassette Transporter, Subfamily B, Member 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The protein kinase C inhibitor CGP 41251, a staurosporine derivative with antitumor activity, reverses multidrug resistance. https://app.cochat.ai/papers/10.1002/ijc.2910570119
- The paper
- Utz, I., Hofer, S., Regenass, U., Hilbe, W., Thaler, J., Grunicke, H., & Hofmann, J. (1994). The protein kinase C inhibitor CGP 41251, a staurosporine derivative with antitumor activity, reverses multidrug resistance. International Journal of Cancer. https://doi.org/10.1002/ijc.2910570119
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.